Stryker, MacMillan reach deal on severance; AccessClosure launches MynxGrip vascular closure device;

@FierceMedDev: AngioDynamics' new chief playing offense and ready for risk. Via @Business_Review. Article | Follow @FierceMedDev

> Former Stryker ($SYK) CEO Stephen MacMillan will get $5.5 million in cash, plus the rights to purchase up to $65 million worth of company stock, as part of his separation agreement. News

> AccessClosure has scored FDA approval and launched the MynxGrip vascular closure device. AccessClosure release

> University of Massachusetts Medical School and MIT researchers are working on technologies that will one day allow cellphones to automatically detect and intervene when a person suffering from post-traumatic stress disorder or substance abuse problems needs support. Item

> Abbott Labs ($ABT) is working with the University of North Texas Science Center to evaluate the company's PLEX-ID instrument for use in analyzing human remains to support missing persons and human trafficking investigations. Abbott Labs release

> Molnlycke Health Care US has acquired the assets of Brennen Medical's burn and wound care business. Release

> Chinese doctors have implanted the first Teligen ICDs from Boston Scientific ($BSX) in that country. The Chinese State Food and Drug Administration approved the Teligen family of devices in November. Boston Scientific release

And Finally... UCLA researchers have developed a new cellphone-based fluorescent imaging and sensing platform that can detect E. coli in food and water. News

Suggested Articles

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.

Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials preparing for a potential crisis.